secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2023-07-18T23:59:59+00:00
Accession:  0001193125-23-188522
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 3.02, 5.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neoleukin to merge with Neurogene; Neurogene stockholders to own ~84% of combined co.
--------------------------------------------------------------------------------

- Neoleukin stockholders will own ~16% of combined company; Neurogene stockholders ~84% on as-converted basis.
- Concurrent ~$95M private financing from investors to close immediately before merger.
- Closing conditions include Neoleukin net cash >= $60M and Neurogene gross proceeds >= $75M from financing.
- Post-merger board of 7 directors: 5 designated by Neurogene, 2 by Neoleukin; CVRs for legacy asset proceeds.
- Support agreements from ~77% of Neurogene and ~21% of Neoleukin stockholders; 180-day lock-up on shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000119312523188522/0001193125-23-188522-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000119312523188522/d506859d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-188522

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer